Legal & General Group Plc grew its holdings in Loxo Oncology, Inc. (NASDAQ:LOXO) by 160.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,042 shares of the biopharmaceutical company’s stock after purchasing an additional 8,028 shares during the quarter. Legal & General Group Plc’s holdings in Loxo Oncology were worth $1,198,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new stake in shares of Loxo Oncology in the second quarter valued at approximately $5,415,000. Federated Investors Inc. PA grew its position in shares of Loxo Oncology by 21,561.6% in the second quarter. Federated Investors Inc. PA now owns 37,258 shares of the biopharmaceutical company’s stock valued at $2,988,000 after purchasing an additional 37,086 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Loxo Oncology by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 54,800 shares of the biopharmaceutical company’s stock valued at $4,395,000 after purchasing an additional 2,400 shares during the last quarter. Nicholas Investment Partners LP acquired a new stake in shares of Loxo Oncology in the second quarter valued at approximately $5,036,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of Loxo Oncology during the second quarter valued at approximately $1,123,000. Institutional investors and hedge funds own 99.98% of the company’s stock.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at $84.18 on Tuesday. The stock has a market cap of $2,520.14, a P/E ratio of -14.44 and a beta of 2.54. Loxo Oncology, Inc. has a one year low of $30.51 and a one year high of $95.92.

LOXO has been the topic of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and set a $103.00 price objective (up previously from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Ifs Securities raised shares of Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research note on Tuesday, November 14th. JMP Securities raised shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $77.18 to $95.00 in a research note on Tuesday, November 14th. BidaskClub raised shares of Loxo Oncology from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 12th. Finally, Citigroup reissued a “buy” rating and set a $112.00 price objective (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $90.57.

In other Loxo Oncology news, CEO Joshua H. Bilenker sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $86.49, for a total transaction of $648,675.00. Following the transaction, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $16,969,943.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. Insiders have sold 1,614,555 shares of company stock worth $124,567,942 in the last three months. Insiders own 27.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Legal & General Group Plc Grows Stake in Loxo Oncology, Inc. (LOXO)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/legal-general-group-plc-grows-stake-in-loxo-oncology-inc-loxo/1791403.html.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.